Trial reportStem cell reviews and reports2021
Multidimensional Proteomic Approach of Endothelial Progenitors Demonstrate Expression of KDR Restricted to CD19 Cells.
Open access · bronzeAbstract readClinical TrialMulticenter Study
In one paragraph
Trial report in Stem cell reviews and reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Circulating Endothelial Compartment and Progenitor Cell Dynamics in Idiopathic Pulmonary Fibrosis: Findings from the COFI Trial.Stem cell reviews and reports · 2026Article
- Article
- Comorbidities and Angiogenic Regulators Affect Endothelial Progenitor Cell Subtype Numbers in a Healthy Volunteer Control Group.Stem cell reviews and reports · 2024Article
- Mobilization of Endogenous CD34+/CD133+ Endothelial Progenitor Cells by Enhanced External Counter Pulsation for Treatment of Refractory Angina.International journal of molecular sciences · 2024Article
- The Onset of Intussusceptive Angiogenesis in COVID-19 Patients Might Come from the Mobilization of Stem Cell Sub-Populations Expressing the Hemangioblast Marker CD143.Stem cell reviews and reports · 2024Article
- Hemocompatibility and biophysical interface of left ventricular assist devices and total artificial hearts.Blood · 2024Review
- VEGF-A plasma levels are associated with impaired DLCO and radiological sequelae in long COVID patients.Angiogenesis · 2024Article
- HIV Promotes Atherosclerosis via Circulating Extracellular Vesicle MicroRNAs.International journal of molecular sciences · 2023Article
- High-throughput proteomics: a methodological mini-review.Laboratory investigation; a journal of technical methods and pathology · 2022Review
- (Epi)transcriptomics in cardiovascular and neurological complications of COVID-19.Journal of molecular and cellular cardiology plus · 2022Review
- Regulation of Endothelial Progenitor Cell Functions in Ischemic Heart Disease: New Therapeutic Targets for Cardiac Remodeling and Repair.Frontiers in cardiovascular medicine · 2022Review
- COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects.Angiogenesis · 2021Review
- Current concepts on endothelial stem cells definition, location, and markers.Stem cells translational medicine · 2021Review
- Anticoagulation Before Hospitalization Is a Potential Protective Factor for COVID-19: Insight From a French Multicenter Cohort Study.Journal of the American Heart Association · 2021Article
- Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient.Stem cell reviews and reports · 2021Article
- Safety and efficacy of autologous non-hematopoietic enriched stem cell nebulization in COVID-19 patients: a randomized clinical trial, Abu Dhabi 2020.Translational medicine communications · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 3 institutions in 3 countries.
Coralie L GuerinInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Léa GuyonnetInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Guillaume GoudotVascular Medicine Department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, Université de Paris, F-75015, Paris, France.
Dominique RevetsDepartment of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Maria KonstantinouDepartment of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Anna ChipontDepartment of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Richard ChocronPARCC, INSERM, Université de Paris, F-75006, Paris, France.
Adeline BlandinieresInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Lina KhiderVascular Medicine Department and Biosurgical Research Laboratory (Carpentier Foundation), AH-HP, Georges Pompidou European Hospital, Université de Paris, F-75015, Paris, France.
Jeanne RancicInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Christophe PeroninoInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Benjamin DebucInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Audrey CrasInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Camille KnospPARCC, INSERM, Université de Paris, F-75006, Paris, France.
Christian LatremouilleInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Antoine CapelCarmat SA, Vélizy-Villacoublay, France.
Markus OllertDepartment of Infection and Immunity, Luxembourg Institute of Health, Strassen, Luxembourg.
Jean-Luc DiehlInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Piet JansenCarmat SA, Vélizy-Villacoublay, France.
Benjamin PlanquetteInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Olivier SanchezInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Pascale GaussemInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Tristan MiraultPARCC, INSERM, Université de Paris, F-75006, Paris, France.
Alain CarpentierInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
Nicolas GendronInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France.
David M SmadjaInnovative Therapies in Haemostasis, INSERM, Université de Paris, F-75006, Paris, France. david.smadja@aphp.fr.ORCID http://orcid.org/0000-0001-7731-9202
Inserm · FRLuxembourg Institute of Health · LUUniversité Paris Cité · FR
Funding
ANR and Fondation de France SARCODOAP-HP mécénat crise COVID-19 - GHU APHP.CUP
Abstract
Endothelial progenitor cells (EPCs) are involved in vasculogenesis and cardiovascular diseases. However, the phenotype of circulating EPCs remains elusive but they are more often described as CD34
Indexed as
Gene Expression RegulationHeart, ArtificialAntigens, CD19COVID-19Endothelial Progenitor CellsFemaleHumansMaleMiddle AgedProteomicsSARS-CoV-2Vascular Endothelial Growth Factor Receptor-2Antigens, CD19CD19 molecule, humanKDR protein, humanVascular Endothelial Growth Factor Receptor-2Bioprosthetic total artificial heartC-kitCOVID-19Endothelial progenitorsStem cellsVEGFR-2/KDR
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.